Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Debt-to-Asset : 0.76 (As of Sep. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Debt-to-Asset?

Sucampo Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $0.0 Mil. Sucampo Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $293.5 Mil. Sucampo Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2017 was $388.1 Mil. Sucampo Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2017 was 0.76.

Sucampo Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Sucampo Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Debt-to-Asset Chart

Sucampo Pharmaceuticals Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Debt-to-Asset

Get a 7-Day Free Trial

0.41

0.39

0.18

0.55

0.56

Sucampo Pharmaceuticals Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Debt-to-Asset	Get a 7-Day Free Trial															0.48	0.56	0.55	0.80	0.76

Competitive Comparison of Sucampo Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sucampo Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's Debt-to-Asset falls into.

Sucampo Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sucampo Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	290.516)	/	520.851
	=	0.56

Sucampo Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2017 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	293.539)	/	388.144
	=	0.76

Sucampo Pharmaceuticals (NAS:SCMP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sucampo Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

Website

http://www.sucampo.com

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Executives

Peter Greenleaf	officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell	director
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan	officer: Sr. Vice Pres., BD & Licensing	C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener	officer: Chief Science Officer	40 GUEST STREET, BOSTON MA 02135
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp	other: Former Officer	4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin	director	18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris	officer: Chief Acctg. Officer, Treas.	C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814